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We previously developed NetPath as a resource for comprehensive manually curated signal transduction pathways. The
pathways in NetPath contain a large number of molecules and reactions which can sometimes be difficult to visualize or
interpret given their complexity. To overcome this potential limitation, we have developed a set of more stringent curation
and inclusion criteria for pathway reactions to generate high-confidence signaling maps. NetSlim is a new resource that
contains this ‘core’ subset of reactions for each pathway for easy visualization and manipulation. The pathways in NetSlim
are freely available at http://www.netpath.org/netslim.
Database URL: www.netpath.org/netslim
.............................................................................................................................................................................................................................................................................................
Introduction
Advances in methods for the detection and identification
of proteins, particularly their post-translational modifica-
tions (PTMs) and protein–protein interactions (PPIs) have
contributed enormously to our understanding of signal
transduction. However, such information available in the
literature is heterogeneous with respect to molecules
and their reactions in various signal transduction pathways.
The spatiotemporal organization and behavior of proteins
still remains a sizeable challenge to the scientific commu-
nity. Although these concerns have yet to be fully ad-
dressed, currently available signaling reactions do provide
a basic framework to investigate the molecular mechanisms
and dynamics of signal transduction events. Indeed, com-
posite maps of these signaling events are often used to
visualize, hypothesize and to develop mathematical
.............................................................................................................................................................................................................................................................................................
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.............................................................................................................................................................................................................................................................................................models to predict the behaviors of normal and diseased
cells (1, 2). Moreover, these signaling maps can also be over-
laid with biological data from various high-throughput ex-
perimental platforms to obtain an integrated view of
biological processes (3, 4).
NetPath (http://www.netpath.org) is a publicly available
resource of comprehensively and manually curated signal
transduction pathways (5) developed previously by our
group using an open-source pathway annotation tool,
PathBuilder (6). NetPath already includes numerous mol-
ecules and reactions which are not included in pathways
or signaling maps available elsewhere (7). It can be
argued that although all of the reactions in NetPath are
derived from the literature, many of the pathways in
NetPath are already too unwieldy because of the large
number of molecules in each pathway and the large
number of reactions. The Gene Ontology consortium de-
veloped GO Slim as a way to generate a list of core GO
terms (8). Here, we applied more stringent criteria to path-
ways in NetPath to develop a similar ‘slim’ version of path-
ways containing only high-confidence reactions as a means
to generate less complex and more easily visualized version
of individual signaling pathways. These newly generated
‘slim’ signaling maps, designated NetSlim, are freely avail-
able through http://www.netpath.org/netslim.
Development of NetSlim
NetPath currently contains a number of cancer and immune
signaling pathways whose reactions are available in stand-
ard formats including proteomics standards initiative—mo-
lecular interactions (PSI–MI) and biological pathway
exchange (BioPAX) formats (5, 9–12). The pathway reac-
tions are categorized as: (i) PPIs comprising both binary
and complex interactions; (ii) enzyme–substrate reactions
comprising both direct and induced catalyzed reactions;
(iii) transport events that specify movement of molecules
across distinct subcellular compartments; and (iv) differen-
tial gene expression coupled to transcriptional regulators, if
known. Each reaction is linked directly to the published lit-
erature and information pertaining to the host organism,
cell-type and subcellular location.
Criteria for NetSlim
In generating NetSlim, we applied the following inclusion
criteria to extract a high confidence set of reactions from
pathways in NetPath: (i) reactions supported by at least two
research articles; (ii) reactions shown to occur in multiple
cell types (iii) PPIs reported through high-throughput ana-
lyses, as well as induced PTMs identified using mass spec-
trometry are included if they are supported by any other
experimental method; (iv) components of well established
protein complexes even if they do not meet other criteria;
and (v) molecules or reactions described in expert review
articles. Schematic representation of the NetSlim criteria is
provided in Figure 1. Reactions that fulfilled one or more of
the above criteria were included in NetSlim.
Graphical representation of NetSlim
The signaling pathway maps of NetSlim were generated
using the PathVisio tool which facilitates editing and dis-
play of biological pathways (13). PathVisio is an improved
visualization tool which incorporates all the features of
GenMAPP (14). All molecular reactions that occur down-
stream of activated receptors are represented by solid
edges, which depict direct interactions/reactions, or by
dashed edges, which depict indirect/induced events.
Signaling nodes are depicted based on the ability of mol-
ecules to interact with their partners, and on the availabil-
ity of protein regulators for cross-talk with other signaling
modules. The topology of the pathway, which determines
whether a given molecule lies upstream or downstream
from another reference molecule, is generally dependent
on the biological information obtained from studies using
mutants or inhibitors of specific molecules. The edges rep-
resenting various PPIs, enzymatic reactions or protein trans-
location events are distinguished from each other by
distinct colors. NetSlim maps with detailed legends are
available at http://www.netpath.org/netslim. Pathway
maps with nodes hyperlinked to specific NetPath molecule
page and the edges linked to their corresponding citations
can be obtained by clicking on ‘map with citation’ option in
the NetSlim pathway pages. The browsing features and the
information provided in NetSlim are shown in Figure 2 with
TGF beta pathway as an example.
NetSlim map of the TGF-b pathway as a model
The signal transduction mechanisms underlying the patho-
physiological activities of transforming growth factor-b
(TGF-b) have been extensively studied since its discovery
nearly 30 years ago. Mammals express three TGF-b isoforms
(i.e. TGF-b1, TGF-b2 and TGF-b3) that are encoded by dis-
tinct genes in a tissue-specific and developmentally regu-
lated manner (15). In addition, numerous studies have
clearly established TGF-b as a multifunctional cytokine
that plays essential roles in regulating virtually all aspects
of mammalian development and differentiation, and in
maintaining mammalian tissue homeostasis (15–18). Even
more remarkably, malignant cells have evolved a variety
of complex mechanisms capable of circumventing the
tumor suppressing activities of TGF-b, and in doing so, typ-
ically convert the functions of TGF-b to that of a tumor
promoter, particularly the induction of carcinoma epithe-
lial–mesenchymal transition, invasion, and dissemination to
distant organ sites (15–18). This peculiar conversion in
TGF-b function is known as the ‘TGF-b Paradox’, which
underlies the lethality of TGF-b in metastatic cancer cells.
Thus, elucidating the effectors and signaling modules
.............................................................................................................................................................................................................................................................................................
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opment of novel neoadjuvants capable of effectively tar-
geting the TGF-b pathway to significantly improve the
clinical course of patients with cancer, fibrosis or immuno-
logic disorders.
TGF-b is secreted from cells as a latent homodimeric poly-
peptide that becomes tethered to the extracellular matrix
by latent-TGF-b-binding proteins. Mature TGF-b isoforms
are activated and liberated from extracellular matrix
depots by a variety of mechanisms, including proteolysis,
reactive oxygen species, changes in pH and physical inter-
actions with integrins, thrombospondin-1 or SPARC (19–22).
Once activated, mature TGF-b initiates transmembrane
signaling by binding to two distinct transmembrane Ser/
Thr protein kinases, termed TGF-b type I (TbR-I) and type
II (TbR-II) receptors (23–25). In some cells and tissues, TGF-b
also binds to a third cell surface receptor, TGF-b type III
(TbR-III), which transfers TGF-b to TbR-II and TbR-I (26).
Full activation of these cytokine:receptor ternary complexes
transpires upon TbR-II-mediated transphosphorylation and
activation of TbR-I (27, 28), which then phosphorylates and
activates the latent transcription factors, Smad2 and Smad3
(29, 30). Afterward, phosphorylated Smad2/3 interact phys-
ically with Smad4, with the resulting heterotrimers trans-
locating into the nucleus to regulate the expression of
TGF-b-responsive genes (29, 30). These Smad-dependent
NetPath
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Figure 1. Schematic representation of the criteria used to select high-confidence pathway reactions from NetPath for NetSlim.
Reactions supported by at least two research articles are considered confident. Reactions shown to occur in multiple cell types
for specific pathways are also included. NetSlim further incorporates reactions reported through high-throughput analyses
which were validated by a focused experiment (in the same research article or another research article). The interactions
between components of known protein complexes are included to obtain a general view of a pathway. Molecules or reactions
established through expert review articles are considered for NetSlim in order to provide the core set of reactions in a given
pathway.
.............................................................................................................................................................................................................................................................................................
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the cytoplasm by their interaction with a variety of adapter
molecules, including SARA, Hgs, PML and Dab2 (31–34), and
with Smad7 (35, 36), whose inhibitory activity is modulated
by STRAP, AMSH2 and Arkadia (37–39); and in the nucleus
by their interaction with a variety of transcriptional activa-
tors and repressors that occur in a gene- and cell-specific
manner (40). In addition to activating canonical Smad2/
3-dependent signaling, accumulating evidence clearly
links the development of a variety of human pathologies
to aberrant coupling of TGF-b to its noncanonical effector
molecules. Included in this ever expanding list of non-
canonical signaling molecules stimulated by TGF-b are
PI3K (41), AKT (42), mTOR (43), integrins (44) and focal
adhesion kinase (45), and members of the MAP kinase
[e.g. ERK1/2 (46), JNK (47) and p38 MAPK (48)] small
GTP-binding proteins (e.g. Ras, Rho and Rac1) (18).
The TGF-b-signaling pathway constructed in NetPath cur-
rently contains 226 proteins that participate in 482 reac-
tions comprised of 340 molecular association events, 105
enzymatic events and 37 translocation events. Graphical
representation of these molecules in their entirety is quite
cumbersome, thus making their meaningful interpretation
difficult for biologists users of the NetPath resource.
Further many NetPath molecules and their reactions are
supported by either single publications or derived from
high-throughput experiments lacking secondary experi-
mental validation. While the entire network is useful, espe-
cially to gain coverage in gene expression analyses, users
often want to see only the high confidence regions of a
Figure 2. An overview of NetSlim. The NetSlim home page has options to browse the pathway maps. A description of the criteria
used for NetSlim is available as a separate tab. Choosing a pathway such as the TGF beta signaling pathway, the ‘Pathway map’
tab provides access to the TGF-b NetSlim pathway map image and the ‘Description’ tab which has a brief description of the
pathway. The ‘map with citation’ provided in the NetSlim pathway page contains molecules linked to specific NetPath molecule
pages and their reactions linked to their corresponding citations. NetSlim maps can be downloaded in different file formats from
specific pathway pages. The NetSlim data is also available to download in BioPAX, PSI-MI and SBML formats. A ‘Feedback’ page
allows users to provide comments about the NetSlim resource. A link to NetSlim is provided on each pathway page in NetPath
and vice versa.
.............................................................................................................................................................................................................................................................................................
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now involved experts from the field to contribute their
knowledge to NetSlim with regard to the inclusion or ex-
clusion of molecules in high confidence datasets. For in-
stance, the presented NetSlim model of TGF-b pathway
possesses 121 proteins involved in 252 reactions with 173
molecular associations, 60 enzyme catalysis reactions and
19 translocation events, almost half the size of the full
NetPath pathway. Review articles contributed to the inclu-
sion of 30% of the reactions in TGF beta NetSlim pathway
map. There were many reactions which were derived from
high-throughput experiments but were not included be-
cause no further validation was conducted.
As such, this TGF-b NetSlim model represents the ‘core
TGF-b pathway’ parsed from the less stringent and all inclu-
sive resource, NetPath. Despite its trimmed appearance, our
NetSlim model still presents more molecules and reactions
as compared to major publicly available pathway resources
containing the same pathway, such as Kyoto Encyclopedia
of Genes and Genomes (KEGG) (49), National Cancer
Institute’s Pathway Interaction Database (PID) (50),
Science’s Signal Transduction Knowledge Environment
Figure 3. TGF-b pathway in NetSlim. The TGF-b pathway map represents the molecular reactions induced by the binding of TGF-b
1 to TGF-b receptor complex. The annotated NetSlim pathway for TGF-b possesses 121 proteins involved in 252 reactions with 173
molecular associations, 60 enzyme catalysis reactions and 19 translocation events. The nodes and edges represent the molecules
and their reactions, respectively. A key for the various symbols, colors and abbreviations used in the pathway diagram is
provided.
.............................................................................................................................................................................................................................................................................................
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.............................................................................................................................................................................................................................................................................................(STKE) Connections Maps (51), Reactome (52) or PANTHER
(53). Some of the pathway resources developed by commer-
cial entities have been customized to better reflect their
available product line and reagents, thus presenting a
skewed and distorted view of the underlying signal
transduction pathways. Our new high confidence map of
the TGF-b signaling system is shown in Figure 3. The
NetSlim criteria have greatly diminished the complexity of
the current pathway map and we hope that they will prove
useful to the community.
Figure 4. Comparative statistics of molecules and reactions in NetPath and NetSlim. The bar diagram represents the total number
of molecules (A) and reactions (B) in signaling pathways in NetSlim and NetPath.
.............................................................................................................................................................................................................................................................................................
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The NetSlim criteria used to extract high confidence
reactions from NetPath have considerably reduced the
complexity of the pathway maps. However, as mentioned
above, these pathway maps contain more molecules and
reactions than other pathway resources available in the
public domain. We have captured reactions described in
the review articles while many others are still not included
in reviews of the respective pathways in spite of being
high confidence. The reactions identified in multiple cell
types could be captured from single or multiple research
publications and contribute to the list of high-confidence
reactions. A comparison between the total number of mol-
ecules and the reactions in NetSlim and NetPath is provided
in Figure 4.
Data availability
Twenty NetSlim maps are currently available, one for each
currently available NetPath pathway. NetSlim maps are
freely available to download in .gpml and .mapp formats
to facilitate overlay of gene or protein expression data. The
NetSlim data is available to download in BioPAX, PSI-MI
and SBML formats which can be used for the visualization
and analysis using software such as Cytoscape (54),
Ingenuity pathway analysis, Visualization and layout ser-
vices for BioPAX pathway models (VISIBIOweb) (55) or
Chisio BioPAX Editor (ChiBE) (56). The NetSlim maps are
also available in PNG, and PDF formats for visualization
and presentation. All data is made available under the
Creative Commons license version 2.5 (57).
Future directions
Gene Ontology terms will be provided whenever functional
significance of the nodes or edges are assayed using inhibi-
tors, mutants, knockouts or silencing studies. We anticipate
making both NetPath and NetSlim versions available for
each pathway as they are curated by our team. We are
also planning on making the pathway maps available in
the Systems Biology Graphical Notation (SBGN) (58)
format in the near future. Finally, we will keep this resource
somewhat flexible so that the criteria can be updated de-
pending upon input from the community and pathway
experts.
Conclusion
Expanding application and increasing demand of various
high-throughput techniques in proteomics have greatly
accelerated the pace by which mechanistic details of signal
transduction pathways are uncovered. Given the enormity
of molecular reactions in the context of pathways already
described to date, it is clear that we need to initiate sys-
tematic efforts at developing comprehensive pathway
resources. NetSlim is an initial step to develop high-
confidence pathway-specific reaction maps. We hope to in-
volve the biomedical community as a means to improve the
quality and accuracy of pathways in NetSlim and to keep
them updated on an ongoing basis. We hope to establish a
model where NetPath and NetSlim versions of individual
signaling pathways will be curated centrally by our team
and published in peer-reviewed journals with pathway
authorities and other contributing biologists from the com-
munity as coauthors. Finally, we believe that NetSlim will
serve the biomedical community in directing and undertak-
ing novel pathway-based systems biology approaches that
have hitherto not been possible.
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